Topical therapy for methicillin-resistant staphylococcus aureus colonization: Impact on infection risk

Infection Control and Hospital Epidemiology

Volumn 30, Issue 7, 2009, Pages 623-632

  Robicsek, Ari ^a,d   Beaumont, Jennifer L ^d   Thomson Jr , Richard B ^b,d   Govindarajan, Geetha ^c,d   Peterson, Lance R ^b,d  

^a Departments of Preventive Medicine   (United States)

^b Departments of Pathology   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CARRIER; CHILD; CHRONIC LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DECUBITUS; DISEASE COURSE; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHYSICIAN; RETROSPECTIVE STUDY; RISK REDUCTION; TOPICAL TREATMENT; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CHLORHEXIDINE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MUPIROCIN; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651100799     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/597550     Document Type: Article

References (36)

1. Shitrit P, Gottesman BS, Katzir M, Kilman A, Ben-Nissan Y, Chowers M. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect Control Hosp Epidemiol 2006; 27:1004-1008.
2. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007; 28:1155-1161.
3. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-418.
4. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006; 43:971-978.
5. Vriens M, Blok H, Fluit A, Troelstra A, Van Der WC., Verhoef J. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002; 21:782-786.
6. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17:811-813.
7. Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillinresistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007; 51:3880-3886.
8. Netto dos Santos KR, de Souza FL, Gontijo Filho PP. Emergence of highlevel mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996; 17:813-816.
9. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000; 21:459-464.
10. Loeb M, Main C., Walker-Dilks C., Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;CD003340.
11. Siegel JD, Rhinehart E, Jackson M, Chairello L, Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. Available at: http://www.cdc.gov/ncidod/ dhqp/pdf/ar/mdroGuideline2006.pdf. Accessed January 4, 2009.
12. Desjardins M, Guibord C., Lalonde B, Toye B, Ramotar K. Evaluation of the IDI-MRSA assay for detection of methicillin-resistant Staphylococcus aureus from nasal and rectal specimens pooled in a selective broth. J Clin Microbiol 2006; 44:1219-1223.
13. Drews SJ, Willey BM, Kreiswirth N, et al. Verification of the IDI-MRSA assay for detecting methicillin-resistant Staphylococcus aureus in diverse specimen types in a core clinical laboratory setting. J Clin Microbiol 2006; 44:3794-3796.
14. Paule SM, Hacek D, Kufner B, et al. Performance of the BD GeneOhm methicillin-resistant Staphylococcus aureus test before and during highvolume clinical use. J Clin Microbiol 2007; 45:2993-2998.
15. Paule SM, Robicsek A, Suseno M, Kaul KL, Peterson LR. Incidence of mupirocin resistance in methicillin-resistant Staphylococcus aureus (MRSA) during universal surveillance and decolonization [abstract C2-1149]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobal Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA.
16. Elixhauser A, Steiner C., Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
17. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36:281-285.
18. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1412-1416.
19. Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180:896-899.
20. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocinbased decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:1467-1474.
21. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002; 35:353-358.
22. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346:1871-1877.
23. Wertheim HF, Vos MC., Ott A, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004; 140:419-425.
24. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8:235-239.
25. Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22:708-712.
26. Cederna JE, Terpenning MS, Ensberg M, Bradley SF, Kauffman CA. Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol 1990; 11:13-16.
27. Watanakunakorn C., Axelson C., Bota B, Stahl C. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Am J Infect Control 1995; 23:306-309.
28. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007; 35:106-114.
29. Fernandez C., Gaspar C., Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995; 35:399-408.
30. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001; 32:1393-1398.
31. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-520.
32. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39:776-782.
33. von Eiff C., Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11-16.
34. Wertheim HF, Vos MC., Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703-705.
35. Kluytmans JA, Mouton JW, Ijzerman EP, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995; 171:216-219.
36. Huang SS, Diekema DJ, Warren DK, et al. Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection. Clin Infect Dis 2008; 46:1241-1247.